

4<sup>th</sup> Translational & Clinical Research Conference

## MYELOPROLIFERATIVE NEOPLASMS

### & Myeloid Diseases

Chair: Dr. Adrian Duek



May 08 2025 | Dan Accadia Herzliya Hotel

**Chairman:** Adrian Duek

**Co-Chairs:** Eran Zimran, Adi Shaham Abulafia, and Meirav Barzilai.

### Preliminary Scientific Program

**08:00-09:00**

Welcome: Adrian Duek, a representative of the Israeli Society of Hematology and Transfusion Medicine

---

#### SESSION I

**Chairs:** To be confirmed

- *Defective neutrophil clearance in myeloproliferative neoplasms drives myelofibrosis via the immune checkpoint target CD24.*  
**Eman Kathib-Massalha**, University of Cambridge, Department of Haematology, Cambridge Stem Cell Institute, UK
- *Epigenetics and epitranscriptomics of hematologic disorders*  
**Gideon Rechavi**, Sheba Cancer Research Center and Tel Aviv University
- *Potential for disease modification in the treatment of Polycythemia Vera.*  
**Claire Harrison**, Guy's and St. Thomas' NHS Foundation Trust, London, UK
- *Management of hypereosinophilic syndrome: the role of mepolizumab.*  
**Nancy Agmon-Levin**, Clinical Immunology, Angioedema and Allergy Unit, Sheba Medical Center

---

**Coffee Break**

---

## SESSION II (Shared with the Greece-Israel Meeting)

**Chairs:** To be confirmed

- *Is it MDS, CCUS, MDS/MPN, or CMML?*  
**Ayelew Tefferi**, Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, US
  - *MDM2 inhibition for the treatment of myelofibrosis.*  
**John Mascarenhas**, Division of Hematology/Oncology at the Icahn School of Medicine at Mount Sinai, NY, US
  - *Diagnosis of Myelofibrosis from peripheral blood.*  
**Gal Dadi**, Department of Molecular Cell Biology, Weizmann Institute of Science
  - *A novel role for the transcription factor NFE2 in regulating redox responses and therapy resistance in MPN.*  
**Heike Pahl**, Center for Tumor Biology, University Hospital Freiburg, Freiburg, Germany
- 

## Lunch

---

## SESSION III

**Chairs:** To be confirmed

- *Use of whole exome NGS myeloid gene panel in the management and diagnosis of MDS and MPN: a case-based discussion.*  
**Vladimir Vainstein**, Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel
  - *Current issues in thrombosis in MPN.*  
**Avi Leader**, Hematology Service, Memorial Sloan Kettering Cancer Center, NY, US
  - *Treatment approach to MDS/MPN cases. Debate and discussion.*  
**Ayelew Tefferi**, Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, US
- 

## Conclusion and Remarks

---